Cube RM’s Post

Leaders in the life sciences & healthcare space are faced with the challenge of buy-in woes from stakeholders across their organizations. It's why these leaders need to consider whether their teams and customers are willing to accept AI solutions, says Head of Data and Digital Engineering at #Customertimes, Dmytro Kobryn. Read insights from Kobryn alongside those from Haider ALLEG, Eugen Burau, Artem Dolgun, Julia Osipova, @Monika Trehan, Mykhailo Maksymenko, and Leonid Parshenkov to discover proven strategies to help your healthcare & life sciences business flourish. Click the following link to read the article: https://hubs.ly/Q02Fn-YJ0 #HLS #Pharma #Basel #DigitalTransformation

If you saw WhizAI at #pharmausa last year, just wait until you see ExplAIn this year! ExplAIn extends the power of Generative AI to uncover anomalies and key drivers that transform your analytics into a story through narratives across all life sciences data sources.

QuartzBio is changing the way #precisionmedicine R&D teams interact with and extract value from #biospecimen and #biomarker #data with AI-powered intelligence. Ask a question, get an answer, and begin your journey from chaos to insight across the entire precision medicine lifecycle. Join Adam S. Brown, PhD as he presents: "AI-Enabled Biomarker Intelligence: Harnessing Insights Across Clinical Programs with the Power of Conversation" where we’ll demonstrate how #conversationalAI empowers users to extract sample and #biomarker information. Can’t wait? We get it. Learn more about our enterprise Biomarker Data Management (eBDM) SaaS product: https://lnkd.in/ekh8ywat

Leaders in the life sciences & healthcare space are faced with the challenge of buy-in woes from stakeholders across their organizations. It's why these leaders need to consider whether their teams and customers are willing to accept AI solutions, says Head of Data and Digital Engineering at #Customertimes, Dmytro Kobryn. Read insights from Kobryn alongside those from Haider ALLEG, Eugen Burau, Artem Dolgun, Julia Osipova, @Monika Trehan, Mykhailo Maksymenko, and @Leonid Parshenkov to discover proven strategies to help your healthcare & life sciences business flourish. Click the following link to read the article: https://hubs.ly/Q02Kz3T10 #HLS #Pharma #Basel #DigitalTransformation

Authenticx partners with pharma manufacturers and life science enterprise to harness the ✨ power of conversations✨ to support patient access, brand insights, vendor management, and risk mitigation. Our technology leverages AI capabilities to aggregate and report on prevalent topics and trends. ➕ bonus: this conversation data likely already exists inside your organizations See how we work with Life Sciences to aggregate topics and trends by download our product guide ➡️ https://hubs.li/Q02GZxgM0

Leaders in the life sciences & healthcare space are faced with the challenge of buy-in woes from stakeholders across their organizations. It's why these leaders need to consider whether their teams and customers are willing to accept AI solutions, says Head of Data and Digital Engineering at #Customertimes, Dmytro Kobryn. Read insights from Kobryn alongside those from Haider ALLEG, Eugen Burau, Artem Dolgun, Julia Osipova, @Monika Trehan, Mykhailo Maksymenko, and @Leonid Parshenkov to discover proven strategies to help your healthcare & life sciences business flourish. Click the following link to read the article: https://hubs.ly/Q02J56R10 #HLS #Pharma #Basel #DigitalTransformation

Are you excited about the future of digital transformation in #pharma? Join our panel at BioTechX Europe 2024 on Oct 9 at 17:25 CET, where industry experts, led by Andrei Doibani, will dive into the power of #AI and data architecture in revolutionizing #healthcare. You don’t want to miss this! Get the details: https://lnkd.in/gwU_GTft #BioTechX #FluidicEnterprise

Struggling with combining #multimodal data to generate insights? A top 20 #pharma solved this challenge using TileDB and Zifo. Curious how they did it? We'll break it down in our upcoming webinar on November 21st. Chad, our presenter, explains it all 👇

A number of you have asked me about #RxY and my new role So, a quick intro to why the excitement here is palpable Of key interest to pharma #insight and #marketing managers… The #WHY of RxY, is meeting an otherwise unmet need, namely Quantifying the real reasons behind treatment choices To #leavelesspatientsbehind What we do differently…   Quantitative level samples with qualitative depth & richness of insight Utilising AI, unprompted, probed surveys combined with a novel research methodology We get you inside the physician’s mind 🧠 at the moment they’re making their decision To truly understand the Rx decision making that is ACTUALLY happening out there in your market Properly prepare to win as many of your identified patients as possible, by understanding: ·     Which treatments did they consider/not consider, and why? ·     Why did they consider a treatment but not use it? ·     Why did they choose the treatment they did? ·     How does this change by line of therapy or type of patient? It would be great to hear any thoughts. Have you tried to answer these questions before and were there any limitations to the data? __________ Syndicated, dynamic patients, across the main EU5 & globally. Connect or reach out to find out more.

“The stakes are high: effective cost-value management is not just a matter of financial responsibility but a crucial determinant of patient outcomes and the sustainability of healthcare systems.” In their latest article, Paul Archer, Chief Commercial Strategy Officer; Zachary Heim, Director of Business Analytics, Insights, & Strategy; and Daniel Cummings, Senior Vice President, Global Head of Business Strategy, Insights, & Analytics, dive into how advanced technologies like AI and data analytics are transforming the life sciences industry. Key insights include: - The importance of Value-Based Pricing (VBP) in aligning financial investments with patient benefits. - How AI and data analytics streamline drug development, providing predictive insights and enhancing stakeholder engagement. - The role of adaptive clinical trials and real-world evidence (RWE) in reducing costs and improving the efficiency of bringing new therapies to market. Read the full article to explore how they’re helping shape a more sustainable and patient-focused future in life sciences: https://lnkd.in/ge8j9dkX #LifeSciences #Innovation #Healthcare #Pharmaceuticals #AI #DataAnalytics #CostValue #PatientCare